Author

M. Le Gars

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 2 Assay:proteomics· 2 Organism:rat· 1

Frequent Co-Authors

H. Schuitemaker· 3 shared J. Sadoff· 3 shared G. van Roey· 2 shared N. Guimera· 2 shared A. Chandrashekar· 1 shared A. Kay· 1 shared B. Brandenburg· 1 shared C. Blish· 1 shared

Activity by Year

2019-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

H. Schuitemaker

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

M. Jongeneelen, K. Kaszas, D. Veldman, J. Huizingh, R. van der Vlugt, T. Schouten, D. Zuijdgeest, T. Uil, G. van Roey, N. Guimera, M. Navis, R. Bos, M. Le Gars, J. Sadoff, L. Muchene, , B. Brandenburg

This study evaluates the neutralizing activity of Ad26.COV2.S vaccine sera against SARS-CoV-2 variants, finding reduced effectiveness against Beta and Gamma but less reduction against Delta.

bioRxiv · Jul 1, 2021 · PreprintImmunology

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

bioRxiv · Jun 9, 2021 · PreprintImmunology

SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques

R. Roozendaal, L. Solforosi, D. Stieh, J. Serroyen, R. Straetemans, F. Wegmann, S. K. Rosendahl Huber, J. E. M. van der Lubbe, J. Hendriks, M. le Gars, L. Dekking, D. N. Czapska-Casey, N. Guimera, S. Janssen, S. Tete, , R. Zahn

This study shows that Ad26.COV2.S vaccine provides long-lasting protection in rhesus macaques, predicted by binding and neutralizing antibody levels against SARS-CoV-2.

bioRxiv · Jan 30, 2021Immunology

CD38 contributes to human natural killer cell responses through a role in immune synapse formation

M. Le Gars, C. Seiler, A. Kay, N. Bayless, E. Sola, E. Starosvetsky, L. Moore, S. Shen-Orr, N. Aziz, C. Dekker, P. Khatri, G. Swan, M. Davis, S. Holmes, C. Blish

This study identifies CD38 as a key receptor in human NK cells that facilitates immune synapse formation, enhancing antiviral and antitumor responses.

bioRxiv · May 24, 2019 · PreprintImmunology